Multiple Sclerosis MoA Animation

SCIENTIFIC ANIMATION

Biogen’s product, VUMERITY® (diroximel fumarate), is a first-line oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Although the mechanism of action of VUMERITY® is not fully understood, its active metabolite (MMF) has been shown to activate the Nrf2 pathway, which is involved in the cellular response to oxidative stress, the cause of pathogenesis of MS.

We created this scientific animation to help visualize the science behind this product, to help inform the audience about the mechanism of disease of multiple sclerosis and the action of VUMERITY® in patients.

This educational animation features online as part of the VUMERITY® website.

Are you interested in seeing how our award-winning medical animation can help you?

Random42 constantly strives to innovate in the medical animation space. Get in touch for a consultation on your next project.

TESTIMONIALS

GSK

‘‘For experts, there’s limited time in which they will interact with this content, so getting a message across quickly is crucial, and this medium does it very well.
Product Manager, GSK

Bristol-Myers Squibb

‘‘Their turnaround time sets them apart from the rest of the field. The fact they can turnaround lots of comments in a couple of days is impressive, whereas that took weeks with other agencies we worked with. They’re well above the benchmark.
Oncology Clinical Liaison, Bristol-Myers Squibb

‘‘It was a combination equally of quality of work but also the comfort and confidence that I knew I would be working with PhDs. They gave me the confidence that they would have the ability to understand. The other companies didn’t have those sorts of people on staff, they were just good animators. That was the area where I felt that I could trust Random42 would deliver.’’
Senior Product Manager, Spectranetics

Amgen Logo

‘‘I have been to a lot of conferences and I have seen a lot of videos both from competitors and internally – in my eyes it is night and day. The quality Random42 have is not one step ahead, it is far ahead compared to what I have seen before.’’
Product Manager, Amgen